Therapy Detail

Therapy Name AB61
Therapy Description

AB61 is a 7-deazapurine nucleoside that incorporates into DNA and RNA resulting in DNA/RNA damage thereby repressing protein translation, and is demonstrated to be specifically cytotoxic to cancer cells (PMID: 26819331).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AB61 AB61 is a 7-deazapurine nucleoside that incorporates into DNA and RNA resulting in DNA/RNA damage thereby repressing protein translation, and is demonstrated to be specifically cytotoxic to cancer cells (PMID: 26819331).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable AB61 Preclinical - Cell line xenograft Actionable In a preclinical study, the synthetic nucleoside AB61 demonstrated cytotoxicity in colorectal cancer cell lines in culture and decreased tumor volume and prolonged survival in colorectal cancer cell line xenograft models (PMID: 26819331). 26819331
Unknown unknown ovarian cancer not applicable AB61 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the synthetic nucleoside AB61 resulted in decreased tumor volume in ovarian cancer cell line xenograft models (PMID: 26819331). 26819331
Unknown unknown breast cancer not applicable AB61 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the synthetic nucleoside AB61 resulted in repressed protein translation, decreased tumor volume, and prolonged survival in breast cancer cell line xenograft models (PMID: 26819331). 26819331
Clinical Trial Phase Therapies Title Recruitment Status